Publication Name	World Journal of Clinical Oncology
Manuscript ID	30880
Country	Italy

Received	2016-10-21 09:31
Peer-Review Started	2016-10-23 23:34
To Make the First Decision	2016-12-19 08:48
Return for Revision	2016-12-20 17:23
Revised	2017-07-06 17:37
Second Decision	2017-08-11 07:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-09-01 22:32
Articles in Press	2017-09-01 22:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-13 06:41
Publish the Manuscript Online	2017-09-25 04:24

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Cohort Study
Article Title	Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
Manuscript Source	Invited Manuscript
All Author List	Nevena Skroza, Ilaria Proietti, Nicoletta Bernardini, Veronica Balduzzi, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Sara Zuber, Giuseppe La Torre and Concetta Potenza
Funding Agency and Grant Number
Corresponding Author	Nevena Skroza, MD, Dermatology Unit “Daniele Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Via Firenze snc Polo Pontino, Terracina 04019, Italy. nevena.skroza@uniroma1.it
Key Words	Ingenol mebutate; Actinic keratosis; Facial and scalp lesions; Skin reactions; Dermoscopic feature
Core Tip	Ingenol mebutate 0.015% gel is an effective treatment for non-hypertrophic non-hyperkeratotic actinic keratosis of face and scalp. Facial lesions are more prone to achieve a complete response to this therapy than those located on the scalp. Facial localization and the highest levels of local skin reaction, in particular the amount of crusting, are predictive for complete response to ingenol mebutate 0.015% gel therapy in a real clinical setting.
Publish Date	2017-09-25 04:24
Citation	Skroza N, Proietti I, Bernardini N, Balduzzi V, Mambrin A, Marchesiello A, Tolino E, Zuber S, La Torre G, Potenza C. Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp. World J Clin Oncol 2017; 8(5): 405-411
URL	http://www.wjgnet.com/2218-4333/full/v8/i5/405.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i5.405

Full Article (PDF)	WJCO-8-405.pdf
Full Article (Word)	WJCO-8-405.doc
Manuscript File	30880-Review.doc
Answering Reviewers	30880-Answering reviewers.pdf
Audio Core Tip	30880-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	30880-Conflict-of-interest statement.pdf
Copyright License Agreement	30880-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	30880-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	30880-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	30880-Language certificate.pdf
Supplementary Material	Supplementary_Material_20161020210532.jpg
Peer-review Report	30880-Peer-review(s).pdf
Scientific Misconduct Check	30880-Scientific misconduct check.pdf
Scientific Editor Work List	30880-Scientific editor work list.pdf